IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES

Objective: To evaluate the diagnostic value of Immunohistochemistry (IHC) for finding BRAFV600E mutation in melanoma patients. Study Design: Cross-sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, Jan 2018 to A...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad Umer Ch, Farhan Akhtar, Nighat Jamal, Rabia Ahmad, Sumaira Bukhsh, Hamza Mansur
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	brafv600e mutation immunohistochemistry monoclonal antibody Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d5205509b351480e8f9352c9379000b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5205509b351480e8f9352c9379000b6
record_format	dspace
spelling	oai:doaj.org-article:d5205509b351480e8f9352c9379000b62021-11-25T02:48:30ZIMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES0030-96482411-8842https://doaj.org/article/d5205509b351480e8f9352c9379000b62021-10-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/5955/3643https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To evaluate the diagnostic value of Immunohistochemistry (IHC) for finding BRAFV600E mutation in melanoma patients. Study Design: Cross-sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, Jan 2018 to Apr 2019. Methodology: Hundred histologically confirmed cases of melanoma aged between 18-80 years were included over a period of one year. To create the tissue microarray and to conduct immunohistochemistry with VE1 antibody melanoma lesion samples were selected. Results: Ninety-four cases out of 100, were melanoma positive for BRAFV600E detected on immunohistochemistry (IHC) using a monoclonal antibody. The skin was the primary site in seventy-nine (79%) patients, unknown (metastatic) in nineteen and uveal was only in two cases. The diagnostic significance of immunohistochemistry (IHC) for detecting the BRAFV600E mutation in melanoma patients was independent of age, site and stage at diagnosis (p-value <0.05). Conclusion: Testing of BRAV600E mutation by immunohistochemistry is a rapid, reliable and cost-effective tool in melanoma patients which may further help clinicians in initiating targeted therapy for these patients.Muhammad Umer ChFarhan AkhtarNighat JamalRabia AhmadSumaira BukhshHamza MansurArmy Medical College Rawalpindiarticlebrafv600e mutationimmunohistochemistrymonoclonal antibodyMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 5, Pp 1885-1888 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brafv600e mutation immunohistochemistry monoclonal antibody Medicine R Medicine (General) R5-920
spellingShingle	brafv600e mutation immunohistochemistry monoclonal antibody Medicine R Medicine (General) R5-920 Muhammad Umer Ch Farhan Akhtar Nighat Jamal Rabia Ahmad Sumaira Bukhsh Hamza Mansur IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
description	Objective: To evaluate the diagnostic value of Immunohistochemistry (IHC) for finding BRAFV600E mutation in melanoma patients. Study Design: Cross-sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, Jan 2018 to Apr 2019. Methodology: Hundred histologically confirmed cases of melanoma aged between 18-80 years were included over a period of one year. To create the tissue microarray and to conduct immunohistochemistry with VE1 antibody melanoma lesion samples were selected. Results: Ninety-four cases out of 100, were melanoma positive for BRAFV600E detected on immunohistochemistry (IHC) using a monoclonal antibody. The skin was the primary site in seventy-nine (79%) patients, unknown (metastatic) in nineteen and uveal was only in two cases. The diagnostic significance of immunohistochemistry (IHC) for detecting the BRAFV600E mutation in melanoma patients was independent of age, site and stage at diagnosis (p-value <0.05). Conclusion: Testing of BRAV600E mutation by immunohistochemistry is a rapid, reliable and cost-effective tool in melanoma patients which may further help clinicians in initiating targeted therapy for these patients.
format	article
author	Muhammad Umer Ch Farhan Akhtar Nighat Jamal Rabia Ahmad Sumaira Bukhsh Hamza Mansur
author_facet	Muhammad Umer Ch Farhan Akhtar Nighat Jamal Rabia Ahmad Sumaira Bukhsh Hamza Mansur
author_sort	Muhammad Umer Ch
title	IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
title_short	IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
title_full	IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
title_fullStr	IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
title_full_unstemmed	IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
title_sort	immunohistochemical expression of brafv600e in melanoma cases
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doaj.org/article/d5205509b351480e8f9352c9379000b6
work_keys_str_mv	AT muhammadumerch immunohistochemicalexpressionofbrafv600einmelanomacases AT farhanakhtar immunohistochemicalexpressionofbrafv600einmelanomacases AT nighatjamal immunohistochemicalexpressionofbrafv600einmelanomacases AT rabiaahmad immunohistochemicalexpressionofbrafv600einmelanomacases AT sumairabukhsh immunohistochemicalexpressionofbrafv600einmelanomacases AT hamzamansur immunohistochemicalexpressionofbrafv600einmelanomacases
_version_	1718414667657773056

IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES

Ejemplares similares